Cargando…

Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background

Multiple myeloma (MM) is a common hematological malignancy arising from terminally differentiated plasma cells. In the majority of cases, symptomatic disease is characterized by the presence of bone disease. Multiple myeloma bone disease (MMBD) is a result of an imbalance in the bone-remodeling proc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papanota, Aristea-Maria, Karousi, Paraskevi, Kontos, Christos K., Ntanasis-Stathopoulos, Ioannis, Scorilas, Andreas, Terpos, Evangelos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956742/ https://www.ncbi.nlm.nih.gov/pubmed/33673480 http://dx.doi.org/10.3390/ijms22052375

Ejemplares similares

A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma
por: Papanota, Aristea-Maria, et al.
Publicado: (2021)

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
por: Papanota, Aristea-Maria, et al.
Publicado: (2021)

tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature
por: Karousi, Paraskevi, et al.
Publicado: (2021)

MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia
por: Katsaraki, Katerina, et al.
Publicado: (2021)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
por: Papadimitriou, Maria-Alexandra, et al.
Publicado: (2023)

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas
por: Artemaki, Pinelopi I., et al.
Publicado: (2021)

BCMA in Multiple Myeloma—A Promising Key to Therapy
por: Kleber, Martina, et al.
Publicado: (2021)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma
por: Giannakoulas, Nikolaos, et al.
Publicado: (2021)

Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression
por: Papatsirou, Maria, et al.
Publicado: (2021)

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection
por: Malandrakis, Panagiotis, et al.
Publicado: (2020)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019)

The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma
por: Eid, Michal, et al.
Publicado: (2021)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Identification of Two Novel Circular RNAs Deriving from BCL2L12 and Investigation of Their Potential Value as a Molecular Signature in Colorectal Cancer
por: Karousi, Paraskevi, et al.
Publicado: (2020)

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
por: Papatsirou, Maria, et al.
Publicado: (2023)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Discovery and Comprehensive Characterization of Novel Circular RNAs of the Apoptosis-Related BOK Gene in Human Ovarian and Prostate Cancer Cells, Using Nanopore Sequencing
por: Kontos, Christos K., et al.
Publicado: (2023)

Next-generation sequencing reveals altered gene expression and enriched pathways in triple-negative breast cancer cells treated with oleuropein and oleocanthal
por: Karousi, Paraskevi, et al.
Publicado: (2023)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
por: Terpos, Evangelos, et al.
Publicado: (2019)

Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19
por: Terpos, Evangelos, et al.
Publicado: (2021)

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2018)

High mRNA Expression Levels of Heat Shock Protein Family B Member 2 (HSPB2) Are Associated with Breast Cancer Patients’ Relapse and Poor Survival
por: Sklirou, Aimilia D., et al.
Publicado: (2022)

Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

3′-tRF-Cys(GCA) overexpression in HEK-293 cells alters the global expression profile and modulates cellular processes and pathways
por: Karousi, Paraskevi, et al.
Publicado: (2023)

Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
por: Liatsou, Efstathia, et al.
Publicado: (2023)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Novel circular RNAs of the apoptosis‐related BAX and BCL2L12 genes identified in a chronic lymphocytic leukemia cell line using nanopore sequencing
por: Kontos, Christos K., et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
por: Filippatos, Charalampos, et al.
Publicado: (2023)

Contribution of miRNAs, tRNAs and tRFs to Aberrant Signaling and Translation Deregulation in Lung Cancer
por: Skeparnias, Ilias, et al.
Publicado: (2020)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
por: Terpos, Evangelos, et al.
Publicado: (2021)

Metabolic Disorders in Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2022)

Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value
por: Chira, Panagiota, et al.
Publicado: (2010)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r1us95a6m1q3av20akflofe3he